ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) and Integrated BioPharma (OTCMKTS:INBP – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.
Volatility and Risk
ARS Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Integrated BioPharma has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for ARS Pharmaceuticals and Integrated BioPharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
| Integrated BioPharma | 0 | 0 | 0 | 0 | 0.00 |
Profitability
This table compares ARS Pharmaceuticals and Integrated BioPharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ARS Pharmaceuticals | -56.06% | -38.77% | -23.46% |
| Integrated BioPharma | 1.26% | 3.32% | 2.64% |
Insider & Institutional Ownership
68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.3% of Integrated BioPharma shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 67.4% of Integrated BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares ARS Pharmaceuticals and Integrated BioPharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ARS Pharmaceuticals | $89.15 million | 11.58 | $8.00 million | ($0.81) | -12.89 |
| Integrated BioPharma | $54.35 million | 0.20 | $810,000.00 | $0.01 | 35.63 |
ARS Pharmaceuticals has higher revenue and earnings than Integrated BioPharma. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Integrated BioPharma, indicating that it is currently the more affordable of the two stocks.
Summary
ARS Pharmaceuticals beats Integrated BioPharma on 8 of the 14 factors compared between the two stocks.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
About Integrated BioPharma
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
